China's NMPA has approved Zorifer (zorifertinib), a novel EGFR-TKI developed by Alpha Biopharma and AstraZeneca, for treating non-small cell lung cancer (NSCLC) with CNS metastases. The drug demonstrated significant efficacy in the EVEREST trial, showing a 37% reduction in intracranial progression risk and 17.9-month progression-free survival compared to first-generation EGFR-TKIs.